Table 1

CSF Aβ42 in parkinsonian disorders

Research groupsParticipantsMain findings
Kang et al21PD n=39 (drug-naïve patients), HC n=63Decrease in PD vs HC
Compta et al31Baseline: PD n=27 (non-demented)
18 month follow-up: PD n=16 (non-demented), PD n=11 (dementia converters)
Decrease in dementia converters
Bech et al32PD n=22, PDD n=3, DLB n=11, MSA n=10, PSP n=20, CBD n=3Decrease in DLB vs other disease groups
Hall et al26PD n=90, PDD n=33, DLB n=70, PSP n=45, CBD n=12, MSA n=48, AD n=48, controls n=107Decrease in AD>DLB+PDD
Schoonenboom et al33DLB n=52, PSP n=20, CBD n=16, AD n=512, FTD n=144, VaD n=34, CJD n=6, controls n=275Decrease in AD>VaD>DLB>CBD
Parnetti et al27PD n=38, DLB n=32, AD n=48, FTD n=31, controls n=32
  • Decrease in AD, FTD+DLB vs PD and controls

  • No difference between PD and controls

Andersson et al34DLB n=47, PDD n=17, AD n=150Decrease in DLB vs PDD
Shi et al22Discovery cohort: PD n=126, MSA n=32, AD n=50, controls n=137
Validation cohort: PD n=83
Slight decrease in PD and MSA vs controls
Montine et al28PD n=41, PDD n=11, AD n=49, HC n=150Decrease in PDD vs HC
Süssmuth et al29PSP-RS n=20, PSP-P n=7, MSA-P n=11, MSA-C n=14, PD n=23, controls n=20
  • No difference in parkinsonian syndromes

  • Lower in PSP-RS vs PSP-P

Alves et al23PD n=109, AD n=20, HC n=36Decrease in PD vs HC
Ohrfelt et al30PD n=15, DLB n=15, AD n=66, controls n=55Decrease in AD+DLB vs controls and PD
Compta et al24PD n=20, PDD n=20, HC n=15Decrease in PDD>PD vs HC
Parnetti et al25PD n=20, PDD n=8, DLB n=19, AD n=23, HC n=20Decrease in DLB>PDD>PD
  • AD, Alzheimer's disease; CBD, corticobasal degeneration; CJD, Creutzfeldt–Jakob disease; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; HC, healthy controls; MSA, multiple system atrophy; MSA-C, multiple system atrophy cerebellar type; MSA-P, multiple system atrophy parkinsonian type; PD, Parkinson's disease; PDD, Parkinson's disease dementia; PSP, progressive supranuclear palsy; PSP-P, progressive supranuclear palsy–parkinsonism; PSP-RS, progressive supranuclear palsy–Richardson's syndrome; VaD, vascular dementia.